Glycotope Expands Phase Ib Trial of Combination of Proprietary Anti-Tumor Antibodies to Include Marketed Anti-Tumor Antibodies
- GATTO Study Extension to Evaluate Gatipotuzumab and Tomuzotuximab or marketed anti-EGFR Monoclonal Antibody Drugs in refractory metastatic solid tumors...